Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
232.15
+2.82 (1.23%)
May 26, 2026, 12:49 PM EDT - Market open
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Ligand Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $271.8. The average 1-year stock price forecast is 17.08% higher than the current stock price, while the lowest is $220 (-5.23%) and the highest is $330 (+42.15%).
Price Target: $271.8 (+17.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $260 → $263 | Buy | Maintains | $260 → $263 | +13.29% | May 14, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $262 | Buy | Reiterates | $262 | +12.86% | May 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $289 | Buy | Reiterates | $289 | +24.49% | May 7, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $230 → $255 | Buy | Reiterates | $230 → $255 | +9.84% | Apr 27, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $330 | Buy | Maintains | $330 | +42.15% | Apr 27, 2026 |
Financial Forecast
Revenue This Year
284.30M
from 268.09M
Increased by 6.05%
Revenue Next Year
377.39M
from 284.30M
Increased by 32.74%
EPS This Year
9.01
from 6.13
Increased by 47.01%
EPS Next Year
11.76
from 9.01
Increased by 30.55%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 307.4M | 424.8M | ||||||
| Avg | 284.3M | 377.4M | ||||||
| Low | 260.7M | 339.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.6% | 49.4% | ||||||
| Avg | 6.0% | 32.7% | ||||||
| Low | -2.8% | 19.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 9.59 | 13.45 | |||||
| Avg | 9.01 | 11.76 | |||||
| Low | 8.23 | 10.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 56.4% | 49.3% | |||||
| Avg | 47.0% | 30.5% | |||||
| Low | 34.3% | 14.3% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.